on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has submitted a Form 8.3 disclosure regarding its interests in Avadel Pharmaceuticals plc. Filed under the Irish Takeover Panel Act of 1997, the form details shareholdings exceeding 1% in the company. As of November 3, 2025, Vanguard's interests include ownership of 5,523,668 US$0.01 ordinary shares, equating to a 5.67% stake.
Additional transactions were recorded, with purchases of 5,582 shares and sales of 1,330 shares, all at $18.92 per share. No cash-settled derivative transactions or agreements related to options and derivatives were reported. There are also no indemnities or other agreements influencing securities actions.
This filing is part of regulatory compliance ensuring transparency in dealings with relevant securities during potential takeover situations.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news